Alumis draws Outperform at Oppenheimer
Drug maker Alumis (ALMS) is climbing 7% after investment bank Oppenheimer started coverage of the name with an Outperform ...
There’s a lot to be optimistic about in the Materials sector as 2 analysts just weighed in on Alumis Inc. (ALMS – Research Report) and Corning ...
I am excited to welcome Jack to Alumis as we advance our next-generation TYK2 inhibitor ESK-001 through the Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis and a potential ...
Alumis Inc. (NASDAQ:ALMS – Get Free Report) has been assigned a consensus recommendation of “Buy” from the eight brokerages that are presently covering the stock, Marketbeat reports. Six analysts have ...
Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.
Alumis (ALMS) announced data from a Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics, PK, of single- and multiple-ascending doses of A-005, a potent, selective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback